Frequently Asked Questions
PMTA Process for Vape Products & Nicotine Pouches – FAQs
What is the purpose of the PMTA process for tobacco and nicotine products?
ExpandThe Premarket Tobacco Product Application (PMTA) process allows the FDA to review new tobacco and nicotine products before they are sold. Its purpose is to ensure each product is appropriate for the protection of public health by considering its risks, potential benefits, and impact on users and non-users.
Which vape and nicotine pouch products require a PMTA before they can be sold?
ExpandAny new tobacco product that was not marketed as of the February 15, 2007, predicate date requires FDA authorization through a PMTA. This includes e-cigarettes, vaping devices, nicotine pouches, and any modifications to previously authorized products.
Recent developments in FDA oversight of pouches have clarified compliance expectations, as outlined in nicotine pouch regulatory updates.
How far in advance should a PMTA be submitted before product launch?
ExpandManufacturers should submit applications well before planned commercialization since products cannot legally be sold without authorization. Early submission allows time for review, data requests, and potential amendments before launch.
What types of scientific data are typically included in a PMTA?
ExpandA PMTA usually includes toxicological studies, chemistry data, product stability information, clinical or behavioral studies, and population modeling. These datasets collectively demonstrate how the product affects public health compared to existing tobacco products.
How does the FDA evaluate whether a product is “appropriate for the protection of public health”?
ExpandFDA considers the risks and benefits to both users and non-users, including the likelihood of initiation among youth, potential for cessation among current smokers, product safety, and overall population-level health effects.
Ongoing litigation, including the recent Supreme Court review of flavored vape PMTAs, may shape how this standard is applied in future reviews.
Can marketing continue while a PMTA is under review?
ExpandProducts without FDA authorization cannot legally be marketed in the United States. Manufacturers must wait until a marketing order is granted before selling or distributing the product.
What happens if a PMTA is refused or rejected by the FDA?
ExpandA refused or rejected PMTA cannot move forward in the review process. Manufacturers may submit a new or amended application addressing the deficiencies, but the product must remain off the market until authorization is granted.
How long does the FDA review process usually take for a PMTA?
ExpandThe PMTA review timeline can vary widely depending on the completeness and complexity of the submission. Most reviews take several months to more than a year, with additional time often required for data requests or amendments.
What role do toxicology and chemistry reports play in a PMTA submission?
ExpandThese reports are essential for demonstrating that the product meets safety standards. They provide data on harmful or potentially harmful constituents, toxicological impact, and product consistency across batches.
Are changes to a product’s flavor, nicotine content, or device design considered a new PMTA submission?
ExpandSignificant modifications to product composition, design, or nicotine delivery typically require a new PMTA or supplemental application. FDA must review these changes to ensure they do not introduce new risks.
What is the difference between a PMTA and other tobacco product applications?
ExpandUnlike Substantial Equivalence (SE) or Exemption from SE pathways, a PMTA does not rely on comparisons to a predicate product. Instead, it requires a comprehensive demonstration that the product itself is suitable for marketing based on public health standards.
How does product testing in human studies influence PMTA approval chances?
ExpandHuman studies, such as clinical pharmacokinetic trials or abuse liability assessments, provide key insights into nicotine absorption and behavioral impact. This data strengthens the application by showing how consumers are likely to use the product.
Can multiple products be included under a single PMTA submission?
ExpandGrouping is sometimes allowed if products are similar enough to be supported by the same data set. Each product must still be clearly identified and justified within the application to demonstrate compliance independently.
What are the most common reasons PMTAs for vape products are denied?
ExpandFrequent reasons include insufficient scientific evidence, inadequate youth-use prevention data, incomplete toxicology studies, or missing information that prevents the FDA from fully assessing the product’s public health impact.
How should manufacturers prepare for post-market reporting after PMTA authorization?
ExpandManufacturers must implement systems to monitor sales, adverse events, and product complaints. Timely reporting of this information to the FDA is critical to maintaining marketing authorization and demonstrating ongoing compliance.
FDA Approval
FDA food contact formulation (FCF) notification guidance plays an important role in determining regulatory status of components of a Food Contact Material.
Many industry professionals may be surprised to learn the FDA regulates food packaging. Food packaging is considered an indirect food additive. Determining the regulatory status of your food contact material can be challenging in part because of the number of options to choose from. Those options include:
- Consulting 21 CFR 174-179 to see if the use of the component is an appropriately regulated indirect additive,OR
- Consulting
Food canning establishment regulations are unique among food registration regulations. The FDA requires companies that produce certain shelf-stable, aseptically-sealed low-acid canned or acidified foods to obtain a Food Canning Establishment (FCE) registration. In addition, manufacturers must file documentation with U.S. FDA for each process used in the production of foods subject to these requirements. These submissions are known as a “Process Filing” and each is assigned a unique “Submission Identifier” (SID). This three part system forms the basis for the food canning establishment regulations.
Failing to register either yourself as an importer or your foreign manufacturer could lead to fines and penalties from the US FDA. Registration also demonstrates to distributors, import brokers, and insurers your professionalism and understanding of the regulations.
Avoid U.S. FDA refusals and detentions when shipping canned, bottled, jarred, and other shelf-stable foods in the United States by ensuring your food canning establishment is properly registered and your scheduled processes are properly filed. Please contact our Charlotte or Washington D.C. offices for a complimentary consultation on
FDA Certificate of Origin offer US companies an opportunity to demonstrate FDA approval and/or compliance. Facilities exporting products from the United States to a foreign market are often asked to supply an export “certificate” for products regulated by U.S. FDA. An Export Certificate is a document prepared by U.S. FDA containing information about a product’s regulatory or marketing status.
Contact us today for assistance selecting and completing the correct form.
U.S. FDA currently offers the following types of Export Certificates:
FDA Dietary Supplement Claims
**Please contact our Washington D.C. office if you require an urgent FDA dietary supplement review. Urgent reviews can typically be completed in one business day.**
FDA dietary supplement label review is an important step to complete prior to entering the market. A proper FDA dietary supplement label review will not only identify the rote regulatory requirements, such as statement of identity on the PDP, but also identify claims that pose a risk of reclassification. Reclassification results in a product marketed as a dietary supplement reclassified as a new unapproved drug. This new unapproved drug cannot be on the market.
What is a Dietary Supplement
A FDA dietary supplement label review begins by looking at whether the product meets the dietary supplement definition. The definition for dietary supplements is narrow and only includes ingested products. The question also asks whether the ingredients used are pharmaceutical, GRAS, or require a New Dietary Ingredient submission. Overlooking ingredient classification can be a common mistake in FDA dietary supplement label reviews.
Claims and Intended Use
There are three types of claims made on dietary supplement labels. Those are nutrient content, health/qualified health, and structure function claims. Each type of claim carries a specific definition and requirements that must be followed. A FDA dietary supplement label review identifies those criteria and ensure the claims made comport with the regulations. Skipping this step can lead to a Warning Letter for unapproved claims.
Claims also play an important role in assessing intended use. The intended use is a short-hand for reclassification. The label must objectively demonstrate an intended use through claims, images, and indirect claims to supplement a consumer’s health. Commonly regulatory professionals state a dietary supplement cannot make a claim to “treat/mitigate/cure” a disease or condition. This is an inverse way of saying those claims lead to reclassification as an unapproved new drug. This is perhaps one of the most important parts of a FDA dietary supplement label review.
Label and Labeling
A FDA dietary supplement label review should focus on all aspects of labeling. A common misconception is that FDA authority only extends to the product packaging. This is not true. The FDA exercises authority over “labeling” which has been judicially defined as any material that accompanies the product. This broad definition brings websites, social media, videos, radio programs/ad, and SEO into the scope of a FDA dietary supplement label review. A reviewer should include this material in the advice given.
Please contact our Charlotte or Washington D.C. office for more information on a FDA dietary supplement label review.
At FDA Atty, you have direct access to Marc Sanchez, senior counsel. Marc is available to discuss your case and answer any questions you may have.
Absolutely. We can advise you on what language you can and cannot use on packaging and marketing, so you can make smart decisions for your business.
We have over a decade of experience working with FDA legislation in the food, dietary supplement, beverage, cosmetic, medical device, tobacco, and drug industries.
No. Our practice is limited to proceedings regarding the FDA. This unique focus enables us to have highly specialized knowledge of this area.
No, our practice helps clients from coast to coast and around the world. We connect with clients by phone, e-mail, WhatsApp, and Skype no matter where they are.
Guidance on Self-Affirming GRAS and GRAS Notifications
FDA GRAS Petition Consultants:
Review of Guidance and Regulatory Requirements
FDA infant formula approval and notification is an important and detail process that must be completed before sales begin. Infant formula is a unique area of food regulation. The FDA rightfully views infants as a vulnerable population who rely on the formula as the sole source of nutrition. Parents place a great deal of trust in the product. To maintain that trust the FDA subjects infant formula to additional steps prior to entering the market.
Typically conventional foods (non juice, seafood, or low-acid/acidified canned food (LACF) are simply subject to registration with the FDA. Importers and manufacturers of infant formula not only must register, but also submit a 90-day notification and verification of the formula. A summary of those steps and the timing is provided below.
FDA Medical Device Classification
Verify The FDA Will Not Refuse to Accept Your 510K
When preparing a medical device 510k submission there are a number of important steps. The FDA medical device RTA checklist (a/k/a refuse to accept checklist) can often be an overlooked among the many moving pieces. Among the time-pressure to complete and submit the 510k in order to enter the market it is important to pause to ensure a submission will not be refused. A refused submission will only add to the delays.
The FDA published a Guidance Document (The Guidance for Industry and Food and Drug Administration Staff: Refuse to Accept Policy for 510(k)s) that describes the criteria FDA uses in assessing whether a 510(k) submission meets a minimum threshold of acceptability and should be accepted for substantive review. This Guidance Document provides the FDA medical device RTA checklist for traditional, abbreviated, and special 510ks.
The FDA medical device RTA checklist is not only a tool for industry but a new part of the medical device review. Beginning in 2013 the FDA implemented an administrative review. According to the Guidance Document this review must occur within 15 days of receiving the submission and prior to the substantive review. In the administrative review the FDA medical device RTA checklist is completed by the reviewer to determine if the submission is ready for substantive review or should be refused.
The FDA medical device RTA is dense with detail. The traditional 510k RTA checklist for example fills nearly 25-pages. It covers the basic topics of the 201(h) medical device definition to documentation on software or other performance data. The detailed RTA checlist can lead to a staggering number of refusals. It is important to make the FDA medical device RTA checklist a familiar part of the 510k drafting process as early as possible and every employee involved in the device acquainted with its requirements.
Please contact our Charlotte or Washington D.C. office for a complimentary consultation on FDA medical device regulation, including the FDA medical device RTA checklist.
Overview
FDA Prior Notice Imports is a relatively new requirement. Since December 12, 2003, FDA prior notice must be provided for all food for humans and animals that is imported or offered for import into the United States (Title 21 Code of Federal Regulations (21 CFR), Part 1, Subpart I). This is
FDA Q&A
It depends on your situation and the violation of the legislation. At FDA Atty, we have experience working within the FDA landscape and can ensure we meet the strict timelines set out by the FDA.
Sharing FDA Medical Device Approval
There is a Limited Allowance
Ingredient and Label Compliance Begins with Supplement Definition
FDA dietary supplement definition is the first step in assessing whether a product qualifies for regulation under the supplement provisions of the Food Drug and Cosmetic Act (FD&C). If the product cannot be defined as a dietary supplement than it is often reclassified by the FDA as a drug and subject to harsh penalties for failing to follow the drug regulations.
FDA dietary supplement definition carries two two primary constraints. The first focuses on the ingredients or what the product is made from. The second focuses on how the product is used. The dietary supplement definition is limited to ingredients that are not active pharmaceutical ingredients. There are other constraints such as determining whether the ingredient is GRAS or new and requires a New Dietary Ingredient application. The more common focus is on intended use. This concept focuses on labeling and how the consumer is expected to use the product. This use can focus on whether the product is oral, topical, injected or inhaled. If not oral, then the intended use is for the consumer to use the product as a drug. The use can also center on whether the product is for a medical purpose. This is commonly referred to by the short-hand “cures/mitigates/treats.” The FDA views dietary supplements narrowly as serving to supplement dietary ingredients missing from the diet. There is no accommodation for traditional uses or natural remedies. Understanding these definitions is important when reviewing labels.
FDA Regulations – Resource Center
The FDA regulations are as vast as they are complex. The Agency provides oversight for food, bottled water, juice, seafood, canned food, dietary supplements, tobacco products, drugs, devices, cosmetics, and animal products. In each area is a unique set of FDA regulations. Our collection of blog posts and summaries of FDA regulations are provided below. The FDA regulations in the resource center our grouped by product. Click the links below to visit the FDA regulations related to each product category.
Medical Devices FAQs
FDA-regulated medical devices are products intended for medical purposes (Sec. 201(h)), such as diagnosing, preventing, or treating diseases or conditions. These devices must meet FDA safety and effectiveness standards, and their marketing requires approval or clearance based on risk classification.
The FDA regulates a wide range of medical devices, including diagnostic tools, surgical instruments, imaging devices, and implants. These devices are categorized into three classes (I, II, III), depending on their risk level and regulatory requirements.
Medical devices cannot be marketed or sold in the U.S. without FDA approval or clearance, unless they meet specific exemptions. For high-risk devices, pre-market approval (PMA) is required. Moderate-risk devices (Class II) may only require a 510(k) clearance.
No, you cannot legally sell medical devices in the U.S. without FDA approval or clearance. Selling unapproved devices violates FDA regulations, which could lead to fines, recalls, and other legal consequences.
FDA approval means that a medical device has undergone rigorous review to ensure it is safe and effective for its intended use. For high-risk devices, this approval involves pre-market approval (PMA) to demonstrate compliance with FDA standards.
Medical devices are classified into three categories based on their risk level: Class I (low risk), Class II (moderate risk), and Class III (high risk). The classification determines the regulatory pathway and requirements for approval or clearance.
The 21 CFR (Code of Federal Regulations) part for medical devices is Part 820, which sets the FDA's Quality System Regulations (QSR) for manufacturing practices. It outlines the design, testing, production, and post-market surveillance requirements to ensure device safety and efficacy.
21 CFR Part 820 provides the regulatory framework for the design, production, and quality control of medical devices. It establishes mandatory requirements for quality systems, including design controls, production controls, and corrective and preventive actions to ensure device safety and effectiveness.
21 CFR 807 governs the pre-market notification (510(k)) process for medical devices. It outlines the requirements for manufacturers to submit documentation to the FDA to demonstrate that a device is safe and effective before marketing.
Manufacturers, reprocessors, and repackagers of medical devices must register their establishments with the FDA. They are also required to list their devices with the FDA to ensure compliance with regulatory requirements for marketing and sales.
The Medical Device Reporting (MDR) regulations require manufacturers, importers, and device users to report adverse events and device-related problems to the FDA. These regulations ensure timely action to protect public health from unsafe medical devices.
The 510(k) submission is for devices that are substantially equivalent to existing devices. PMA (Pre-market Approval) is required for high-risk devices, while De Novo submissions are used for novel devices without existing counterparts. Each pathway ensures safety and effectiveness.
A 510(k) submission is required for devices classified as moderate risk (Class II) under FDA guidelines. for devices classified as moderate risk (Class II) under FDA guidelines.
The approval process for a medical device can take several months to a few years, depending on the device's complexity and classification. A 510(k) clearance typically takes about 3 to 6 months, while PMA approval may take 1-3 years. This timing does not account for the data collection needed for a submission.
A U.S. Agent acts as a liaison between foreign medical device manufacturers and the FDA. They are required for non-U.S. manufacturers to facilitate compliance, communications, and FDA-related submissions for devices marketed in the U.S.
FDA labeling requirements ensure that medical devices provide accurate and clear information regarding their intended use, risks, and instructions for safe use. Labels must comply with FDA standards to protect consumers and ensure regulatory compliance.
During an FDA inspection, the agency reviews a company’s quality systems, manufacturing practices, and device records to ensure compliance with FDA regulations. Inspectors assess the company’s adherence to 21 CFR Part 820, among other requirements.
Form 483 is issued when FDA inspectors identify non-compliance with regulations during an inspection. A medical device company must respond within 15 days, outlining corrective actions taken to address the issues and bring operations into compliance.
ISO 13485 is not mandatory but is widely used to demonstrate compliance with FDA regulations. It provides a framework for quality management systems in the medical device industry and helps manufacturers meet FDA requirements for design and production.
ISO 13485 and 21 CFR 820 both establish quality management systems for medical devices, but ISO 13485 is an international standard, while 21 CFR 820 is specific to the FDA. ISO 13485 is often used to support compliance with FDA regulations.
FDA QSR (Quality System Regulations) and ISO 13485 both focus on quality management in medical device manufacturing. QSR is mandatory for FDA-regulated companies, while ISO 13485 is a voluntary standard that supports regulatory compliance and provides a broader international framework.
The FDA has not formally adopted ISO 13485 as the standard for U.S. medical device manufacturers. However, ISO 13485 is often recognized as a valuable tool for ensuring compliance with FDA regulations, and its use is encouraged for global manufacturers.
FDA Enforcement
Absolutely. We can advise you on what language you can and cannot use on packaging and marketing, so you can make smart decisions for your business.
Getting any letter from the FDA can be stressful, but you have options. The first step is to engage an attorney that can help you put a structure in place to extend your deadline. Contact us to book a free 20-minute consultation so you can start the process.
Center for Tobacco Issues More Warning Letters than Any Other Center
Tobacco retailer warning letters are surprisingly active area of FDA regulation. In 2014 the FDA issued 8,220 tobacco retailer warning letters. This surpassed the 470 warning letters issued to device, drug, food, supplement, pet, and cosmetic companies combined. An active area of regulation requires careful attention.
Tobacco retailer warning letters also require a strategic response. The volume of tobacco retailer warning letters indicates a strict application of the Federal Food, Drug, and Cosmetic Act, as amended by the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act) and its regulations in effect, such as the Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco to Protect Children and Adolescents, found at Title 21 of the Code of Federal Regulations, Part 1140 (21 C.F.R. Part 1140).
Tobacco Retailer Warning Letter Can Result in Civil Money Penalties
The FDA’s Center for Tobacco Products (CTP), generally sends Warning Letters to retailers the first time a tobacco compliance check inspection reveals a violation of the federal tobacco laws and regulations that FDA enforces. Failure to promptly and adequately correct all violations and ensure compliance with all applicable laws and regulations may lead to enforcement actions, including Civil Money Penalties. This effort to avoid CMP underscores the need for the right response.
The right response is:
Timely – only 15 days for initial response;
Professional – avoid anger, Constitutional issues like free speech, or accusations about the legality of the tobacco retailer warning letter;
Detailed – the reply should address every concern raised and cite appropriately to the regulations;
Corrective – part of the detail should be a comprehensive plan of action to correct violations.
Following the above outline provides a strong basis to respond to a tobacco retailer warning letter. Please call or Washington D.C. or Charlotte offices if you would like a complimentary consultation for your tobacco retailer warning letter.
It’s important to understand that there are 3 different types of inspections, and the expectations are somewhat different.
- Pre-Approval Inspections (PAI):
Form FDA 483s are public information and thus available through the FDA
FDA Regulations – Resource Center
The FDA regulations are as vast as they are complex. The Agency provides oversight for food, bottled water, juice, seafood, canned food, dietary supplements, tobacco products, drugs, devices, cosmetics, and animal products. In each area is a unique set of FDA regulations. Our collection of blog posts and summaries of FDA regulations are provided below. The FDA regulations in the resource center our grouped by product. Click the links below to visit the FDA regulations related to each product category.
FDA Warning Letter Requirements:
FDA Warning Letter requirements detail the purpose of the Warning Letter. The FDA considers a warning letter simply a notification of serious violations. This notification acts as a placeholder should the FDA decide at any time to pursue remedies for the identified violations. Civil remedies include recalls, seizures, injunctions, and more. Criminal penalties typically follow several unresolved warning letters.
FDA Warning Letter requirements also distinguish how it differs from the Form 483 issued following an inspection. The primary difference between the Form 483 and the Warning Letter is the significance of the Warning Letters. Warning Letters typically represent an escalation of the regulatory violations. Form 483s are issued by inspectors and not reviewed by superiors prior to release. This means only a handful of potential violations are captured in a Form 483. The Warning Letter, however, is issued by a District or Center Director and often reviewed by the Office of Legal Counsel prior to release. Thus, Warning Letters can cover a broader range of topics and reflect more significant violations.
FDA Warning Letter Requirements – Who and When?
The FDA Warning Letter will identify the time to respond – only 15 days – and who to submit the response to. This is the most basic and universal feature of a FDA Warning Letter.
Remember the FDA Warning Letter will appear on the Agency’s public database and be part of the bi-weekly Warning Letter e-mail newsletter.
FDA Form 483 Guidance
FDA Form 483 Guidance provides an overview of the Form 483 Inspectional Observations following a facility inspection. In this part the Form 483 is outlined to provide the reader a better understanding of what role the Form 483 serves for
An FDA enforcement action is a regulatory measure the U.S. Food and Drug Administration takes to ensure companies comply with laws governing food, drugs, medical devices, and other products.
Common FDA enforcement actions include warning letters, recalls, import holds, import alerts, injunctions, seizures, and civil or criminal penalties. These aim to address and correct violations of FDA regulations.
The FDA typically takes action based on inspection findings, product testing, adverse event reports, or complaints indicating violations of safety or regulatory standards.
A warning letter is a notice of regulatory violations requiring correction. A recall is a removal or correction of marketed products that violate FDA laws.
Yes. Companies can appeal certain FDA actions through formal dispute resolution processes, request hearings, or challenge actions in court, depending on the situation.
Consequences can include fines, product seizures, recalls, loss of market access, reputational damage, or even criminal charges in severe cases of noncompliance.
An FDA seizure involves court action to remove non-compliant products from commerce. It can lead to legal proceedings, fines, and reputational damage for the company.
Companies should understand the regulations specific to its products, e.g. drugs, devices, etc., maintain robust quality systems, conduct regular audits, train staff, follow GMPs, claims compliance, and promptly correct issues identified during FDA inspections or internal reviews.
FDA inspections assess compliance with regulations. If serious violations are found, inspections can lead to warning letters, recalls, or other enforcement actions.
Yes. Most enforcement actions, including warning letters, recalls, and consent decrees, are published on the FDA website to inform the public and industry.
The company must investigate, develop a recall strategy, notify affected parties, correct the issue, and report progress to the FDA until the matter is resolved.
Resources include FDA guidance documents, industry associations, regulatory consultants, and legal counsel experienced in FDA matters to help navigate enforcement issues.
An FDA enforcement attorney can advise on response strategies, communicate with the FDA, protect legal interests, and help achieve compliance while minimizing legal risks.
Imports FAQs
Delays often stem from incomplete paperwork, inaccurate product labeling, or missing facility registrations. Issues like unapproved ingredients, lack of required testing, or prior compliance violations can also lead to detentions or refusals at the border. Our import compliance work often focuses on preventing these problems before shipments are sent.
FDA reviews entry documents, labeling, and product history to determine compliance. If the information suggests the product may violate U.S. safety, labeling, or manufacturing standards, the agency can detain it for further evaluation.
Clear, complete documentation and accurate labeling are critical. Working with experienced customs brokers, confirming facility registration status, and understanding FDA import requirements before shipping greatly reduces the risk of costly delays.
DWPE, also known as an import alert, means shipments from your company, facility, or product category are automatically detained based on a history of violations. The FDA requires additional proof of compliance before release.
Removal requires submitting a detailed petition showing consistent compliance over multiple shipments. This typically includes laboratory testing results, updated manufacturing procedures, and other supporting evidence to demonstrate ongoing adherence to FDA requirements.
Refused shipments cannot be distributed in the U.S. Importers must either re-export the goods, destroy them under FDA supervision, or, in rare cases, recondition them to meet compliance standards if permitted.
In certain cases, importers can submit a reconditioning proposal to the FDA. If approved, the goods may be relabeled, reformulated, or otherwise corrected to meet U.S. standards before being released into commerce.
Each category has unique requirements. Food products must comply with FSMA and facility registration rules, dietary supplements must follow cGMP labeling and ingredient standards, and cosmetics must be safe for intended use and correctly labeled under the FD&C Act.
CBP partners with the FDA to enforce import regulations. They inspect shipments, collect duties, and may hold products until the FDA clears them for entry. Their collaboration ensures only compliant products enter U.S. commerce.
Independent testing can provide objective evidence that a product meets safety, purity, or labeling standards. Submitting test results to the FDA can help resolve questions more quickly and secure the release of detained goods.
Key documents include entry filings, prior notice for food, invoices, packing lists, product ingredient lists, and certificates of analysis when applicable. Providing clear, complete, and consistent information minimizes the chance of detention.
A history of violations often triggers closer FDA scrutiny and increases the risk of DWPE placement. Demonstrating corrective actions, compliance improvements, and maintaining a clean import record can gradually reduce detention risk.
FDA typically sets strict deadlines for submitting evidence or reconditioning proposals—often within 10 business days. Failing to respond within the timeframe can lead to a refusal of admission and additional costs.
Importers must notify CBP and FDA of their intent to re-export, provide details of the destination, and complete the process within a defined timeframe. Documentation proving export is required to close the case.
USDA Veterinary Services (VS) Permits & FDA Overlap
A USDA Veterinary Services (VS) Permit authorizes the import, transport, or release of certain animal-derived materials, biological products, and pathogens that could affect animal or public health. It’s generally required for items such as animal tissues, blood products, vaccines, and microorganisms capable of transmitting disease. The permit ensures these materials are handled safely and meet U.S. biosecurity standards before entering the country, often in coordination with FDA import compliance.
While the FDA's import clearance focuses on product safety, labeling, and consumer use, the USDA’s VS Permit system centers on biosecurity and disease prevention. The VS process involves scientific risk assessment and facility biosafety evaluations, whereas FDA reviews address manufacturing quality, labeling accuracy, and intended use. Products may require clearance from both agencies before being released from Customs.
Products that blend biological or animal-derived materials with human-use applications often fall under the jurisdiction of both. Examples include gelatin capsules sourced from bovine tissue, biologics containing animal serum, or dietary supplements with bovine-derived ingredients. These items typically require both FDA compliance and a USDA VS Permit before import.
When an entry is flagged for dual review, U.S. Customs and Border Protection (CBP) holds the shipment until both agencies provide clearance. USDA Animal and Plant Health Inspection Service (APHIS) evaluates biosecurity risk under its VS regulations, while the FDA verifies labeling, facility registration, and product classification. Coordination between the two agencies determines whether the goods can enter commerce or require re-export.
Not all supplements containing animal-derived components need a VS Permit. The requirement depends on the ingredient’s source, processing level, and potential to transmit disease. Fully processed materials, such as hydrolyzed collagen, may be exempt, whereas raw or minimally processed tissues generally require VS authorization or a veterinary health certificate. Products of this kind must also align with FDA labeling and supplement regulations.
FDA label review ensures that product labeling is truthful, accurately identifies animal sources, and complies with applicable requirements for ingredient disclosure. When a product also requires a VS Permit, accurate labeling is essential for USDA verification. Discrepancies between declared ingredients and labeling can lead to detention or permit revocation.
Applications involving pathogens or vectors must include detailed scientific data, biosafety protocols, facility inspection reports, and handling procedures. The USDA reviews the containment level of the facility, transport method, and end-use to ensure compliance with its regulations governing select agents and organisms.
Typical processing times range from 30 to 60 days, although more complex applications may take longer. Delays often occur due to incomplete documentation, missing biosafety details, or unclear end-use descriptions. Early coordination with an experienced regulatory consultant or veterinary specialist can prevent backlogs.
Importing without proper authorization can lead to shipment seizure, re-export, civil penalties, and, in some cases, enforcement action under the Animal Health Protection Act. Repeated violations can trigger enhanced scrutiny for future imports and potential facility audits.
When both agencies regulate a product, labels must meet the FDA’s consumer transparency standards while also satisfying the USDA’s scientific and sourcing disclosures. For example, animal-origin claims must identify the species and processing method, and any health or composition claims must align with FDA labeling rules.
The FDA can delay or refuse entry when USDA authorization is a prerequisite for import. The agencies coordinate through CBP’s automated import systems, and missing VS documentation often results in a “hold for other government agency” status until the USDA review is completed.
VS Permits typically carry a modest processing fee and are valid for one to three years, depending on the type of product. Renewal applications require updated facility and product information. Amendments are necessary if the source, destination, or material specifications change during the permit’s validity period.
The USDA maintains several permit categories under 9 CFR Part 122, including permits for select agents, diagnostic specimens, and controlled vectors. Certain low-risk biological materials may qualify for exemption or simplified entry under specific conditions, but importers must confirm eligibility in writing before shipment.
Effective compliance requires early coordination between regulatory, scientific, and logistics teams. Importers should confirm whether ingredients trigger dual oversight, ensure suppliers are prepared to meet U.S. documentation standards, and align labeling with both USDA and FDA expectations to avoid port delays.
Key resources include USDA APHIS Veterinary Services’ import permit guidance, FDA’s Import and Inspection manuals, and the Automated Commercial Environment (ACE) OGA message sets. Reviewing these references alongside professional legal or regulatory guidance helps ensure complete compliance before shipping.
2025 US Government Shutdown & Hemp Regulation
The shutdown concluded with legislation that significantly tightened federal hemp standards, including new THC limits and exclusions for certain cannabinoid products, reshaping compliance obligations far more than temporary agency slowdowns.
The FDA maintained enforcement authority over unsafe or unlawfully marketed hemp-derived products, while new federal statutory changes simultaneously narrowed what qualifies as lawful hemp, increasing regulatory risk for many cannabinoid formulations.
Yes. The U.S. Food and Drug Administration continues to consider most CBD ingestibles unlawful under existing drug-preclusion and food regulations, regardless of hemp status, while heightened federal hemp standards further restrict many products.
High-priority targets typically include products linked to adverse events, contamination, youth appeal, or misleading disease-treatment claims. Items resembling regulated drugs, making opioid/cancer/anxiety promises, or containing intoxicating cannabinoids (e.g., delta-8) generally face heightened scrutiny from multiple agencies and state consumer-protection offices.
Yes. FDA continued issuing warning letters where public health concerns existed, particularly for products making improper medical claims or marketed toward minors, although administrative timelines may vary based on agency resources.
Ports generally remained operational, but shipments requiring FDA review or regulatory clearance faced heightened scrutiny, especially for cannabinoid products affected by evolving hemp definitions and safety enforcement priorities.
Electronic systems remained available, but regulatory reviews, inspections, and agency feedback could experience delays, particularly for products involving novel cannabinoids or heightened compliance review under evolving federal standards.
Key risks include sudden enforcement swings after reopening, inconsistent interpretations across jurisdictions, supply-chain disruptions, and reputational damage. Companies may also face investor and retailer pressure, insurance exclusions, and contract disputes if products are detained or relabeled due to evolving rules.
State enforcement continued uninterrupted, often intensifying consumer protection actions, while federal agencies retained authority over product legality, labeling claims, and controlled-substance classification under newly revised hemp regulations and evolving federal statutory amendments.
Yes. DEA’s role is Controlled Substances Act enforcement: hemp is excluded only if it meets the federal definition (≤0.3% delta-9 THC, dry weight). Materials exceeding limits, or certain synthetic/intoxicating cannabinoids, can trigger DEA interest alongside local law enforcement during investigations.
Certain enforcement actions and judicial proceedings continued, but regulatory follow-through, administrative processing, and case timelines could slow, particularly in complex hemp and cannabinoid compliance matters involving federal agencies and coordinated enforcement efforts.
Operate as if enforcement will restart abruptly: keep batch records, COAs, validated THC testing, complaint files, and traceability current. Audit labels for prohibited drug claims, maintain adverse-event procedures, and document supplier qualifications so you can respond quickly to inquiries immediately.
Disease-treatment or prevention claims remain the fastest trigger—especially cancer, Alzheimer’s, opioid withdrawal, anxiety/depression, pain, and COVID-style claims—plus pediatric or pregnancy targeting. Also risky: “FDA approved” language, inaccurate cannabinoid content, and inadequate safety/usage directions, and marketing that mimics drugs or dosing.
Backlogs vary by program, but agencies often take weeks to months to normalize after reopening because inspections, reviews, and correspondence queue up. Some analyses expect recovery to extend into the next fiscal year, a federal shutdown regulatory impact for industries.
Because policy signals shift quickly after shutdowns, counsel can map current federal positions, state restrictions, advertising standards, and supply-chain risks into a practical plan. Legal review helps prioritize label edits, testing protocols, and documentation before retailers or regulators request proof.
503A vs 503B Compounding Pharmacies
The distinction centers on who the drugs are made for and how they are regulated. A 503A compounding pharmacy compounds medications based on individual patient prescriptions and is primarily overseen by state boards of pharmacy. In contrast, a 503B outsourcing facility may compound drugs in larger quantities without patient-specific prescriptions but must register with the FDA and comply with additional federal requirements.
503A pharmacies may compound medications tailored to the needs of individual patients when a licensed practitioner issues a valid prescription. These products are typically intended for immediate patient use and must not be essentially copies of commercially available FDA-approved drugs, unless a documented clinical need exists. Questions involving ingredient sourcing or labeling often overlap with broader food, supplement, or animal product regulations.
Outsourcing facilities may compound sterile and non-sterile drugs in bulk for hospitals, clinics, and healthcare systems. Products must appear on FDA-established bulk substance lists and comply with federal safety and quality standards, including adherence to applicable FDA compounding pharmacy regulations.
Drugs compounded under Section 503A are not subject to FDA premarket approval when all statutory conditions are met. However, failure to follow required safeguards—such as prescription requirements or ingredient restrictions—can cause the FDA to treat a compounded product as an unapproved drug.
The FDA inspects facilities operating under Section 503B on a risk-based schedule. These inspections evaluate manufacturing practices, sterility controls, documentation, and overall compliance with federal law. Inspection findings are often made public through FDA enforcement reports.
Interstate distribution is significantly restricted for traditional compounding pharmacies operating under Section 503A. Outsourcing facilities, by contrast, may distribute compounded drugs nationwide if they meet federal registration and quality requirements, making classification critical for lawful distribution.
Labeling expectations differ based on the regulatory pathway. Products from outsourcing facilities must include specific disclosures, lot numbers, and adverse event reporting information, while traditional compounded prescriptions follow more limited labeling rules. Labeling inconsistencies, especially involving ingredient disclosures or intended use, often draw scrutiny during FDA review, similar to issues addressed in dietary supplement and food product compliance matters.
A compounded medication may be deemed unapproved if it fails to meet statutory exemptions, uses prohibited ingredients, or is produced in a manner resembling commercial manufacturing. These determinations are frequently central to the FDA's enforcement actions against compounding pharmacies.
Patient-specific compounding involves preparing a medication in response to a prescription written for an identified individual. Bulk production, which is restricted to outsourcing facilities, allows compounding in advance of prescriptions but requires heightened quality controls and reporting obligations tied to drug compounding compliance.
Misclassification can expose pharmacies to serious regulatory consequences. Operating as a traditional pharmacy while engaging in large-scale production may trigger FDA warning letters, product seizures, or injunctions. These risks are often compounded when facilities misunderstand the boundaries between federal and state oversight.
FDA enforcement actions against noncompliant compounders have included warning letters, product recalls, seizures, injunctions, and consent decrees. These actions are often taken when facilities exceed the scope of permitted compounding, fail to meet sterility standards, or distribute products that qualify as unapproved drugs.
Recent trends in FDA enforcement against compounding pharmacies have led to heightened scrutiny of sterile drug production, quality system failures, and improper promotional practices. Publicly available inspection reports and enforcement announcements highlight the agency’s focus on patient safety and statutory compliance.
Outsourcing facilities must comply with current good manufacturing practice (CGMP) requirements, which are similar to those applied to conventional drug manufacturers. These standards cover quality systems, sterility assurance, environmental controls, testing, and documentation. Traditional compounding pharmacies operating under Section 503A are not subject to CGMPs, provided they meet all statutory conditions for exemption.
A pharmacy may elect to register as an outsourcing facility, but doing so requires significant operational changes. These include FDA registration, CGMP implementation, adverse event reporting, and submission of product information to the agency before compounding under the new status.
Promotional materials are reviewed to ensure they do not imply FDA approval, make unsupported safety or efficacy claims, or misrepresent regulatory status. Improper marketing has been a recurring issue in enforcement cases involving compounded products.
Regulatory guidance is often critical when expanding operations, responding to an FDA inspection, addressing a warning letter, or evaluating whether activities fall under federal oversight. Early legal review can help pharmacies avoid missteps that lead to costly enforcement actions or distribution interruptions involving interstate commerce or import-related compliance.